DE602005004164D1 - Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid - Google Patents

Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid

Info

Publication number
DE602005004164D1
DE602005004164D1 DE602005004164T DE602005004164T DE602005004164D1 DE 602005004164 D1 DE602005004164 D1 DE 602005004164D1 DE 602005004164 T DE602005004164 T DE 602005004164T DE 602005004164 T DE602005004164 T DE 602005004164T DE 602005004164 D1 DE602005004164 D1 DE 602005004164D1
Authority
DE
Germany
Prior art keywords
dissolution
buffer
tamsulosin hydrochloride
formulation
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005004164T
Other languages
English (en)
Other versions
DE602005004164T2 (de
Inventor
Lech Wiackowski
Wieslaw Szelejewski
Andrzej Zaremba
Edyta Pesta-Dynda
Zofia Marchlewska-Cela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instytut Farmaceutiyczny
Original Assignee
Instytut Farmaceutiyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Farmaceutiyczny filed Critical Instytut Farmaceutiyczny
Publication of DE602005004164D1 publication Critical patent/DE602005004164D1/de
Application granted granted Critical
Publication of DE602005004164T2 publication Critical patent/DE602005004164T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602005004164T 2004-08-12 2005-08-12 Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid Active DE602005004164T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL36956604 2004-08-12
PL369566A PL204079B1 (pl) 2004-08-12 2004-08-12 Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
PCT/PL2005/000052 WO2006016829A1 (en) 2004-08-12 2005-08-12 Controlled-release formulation comprising tamsulosin hydrochloride

Publications (2)

Publication Number Publication Date
DE602005004164D1 true DE602005004164D1 (de) 2008-02-14
DE602005004164T2 DE602005004164T2 (de) 2008-12-11

Family

ID=35445840

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005004164T Active DE602005004164T2 (de) 2004-08-12 2005-08-12 Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid

Country Status (7)

Country Link
US (1) US20070298101A1 (de)
EP (1) EP1784161B1 (de)
AT (1) ATE382332T1 (de)
DE (1) DE602005004164T2 (de)
PL (2) PL204079B1 (de)
SI (1) SI1784161T1 (de)
WO (1) WO2006016829A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722458B2 (en) * 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
MX351453B (es) * 2011-12-02 2017-10-16 Pegasus Laboratories Inc Composiciones de liberacion sostenida a base de lipidos anfipaticos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528195D0 (en) * 1985-11-15 1985-12-18 Boots Co Plc Therapeutic compositions
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
WO2003009831A1 (en) * 2001-07-27 2003-02-06 Yamanouchi Pharmaceutical Co., Ltd. Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same
NZ532589A (en) * 2001-11-07 2005-02-25 Synthon Bv Tamsulosin tablets

Also Published As

Publication number Publication date
PL369566A1 (pl) 2006-02-20
EP1784161A1 (de) 2007-05-16
ATE382332T1 (de) 2008-01-15
PL204079B1 (pl) 2009-12-31
US20070298101A1 (en) 2007-12-27
WO2006016829A1 (en) 2006-02-16
SI1784161T1 (sl) 2008-06-30
EP1784161B1 (de) 2008-01-02
DE602005004164T2 (de) 2008-12-11
PL1784161T3 (pl) 2008-05-30

Similar Documents

Publication Publication Date Title
JP6426560B2 (ja) 新規の、効力のあるタペンタドール剤形
DK178702B1 (en) USE OF BINDERS FOR MANUFACTURING STORAGE STABLE FORMULATIONS
Kranz et al. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug
CA2795324C (en) Pharmaceutical compositions comprising hydromorphone and naloxone
HRP20041234B1 (hr) Oblik pramipeksola za doziranje jednom dnevno
ES2642788T3 (es) Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
JP2009538918A (ja) フェニレフリンを含有する徐放薬学的投薬形態
Liu et al. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system
RU2333745C2 (ru) Композиции с контролируемым высвобождением
WO2011053003A2 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
US20190054088A1 (en) Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
TW201334780A (zh) 多西拉敏及吡哆醇及／或其代謝物或鹽之調配物
Charoo et al. Biowaiver monograph for immediate-release solid oral dosage forms: bisoprolol fumarate
HRP20030050A2 (en) Sustained-release preparations of quinolone antibiotics and method for preparation thereof
US20100003322A1 (en) Enteric coated hydrophobic matrix formulation
ATE382332T1 (de) Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid
US20080138411A1 (en) Modified Release Formulations Of Selective Serotonin Re-Uptake Inhibitors
KR20230080461A (ko) 약학적 제형
KR101464053B1 (ko) 4-메틸피라졸 배합물
US20150148388A1 (en) Chemical composition
EP2768487A1 (de) Zubereitung mit verzögerter freisetzung
JP6654426B2 (ja) 医薬組成物
RU2018137590A (ru) Фармацевтические композиции для производного n-пропаргиламина
US20070009596A1 (en) Controlled drug release composition resistant to in vivo mechanic stress

Legal Events

Date Code Title Description
8364 No opposition during term of opposition